DUBLIN – The contest to develop new therapeutics targeting transforming growth factor beta 1 (TGF-beta1) signaling in cancer intensified this week, as both Abbvie Inc. and Scholar Rock Holding Corp.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback